VERIGENE™ Gram-Positive Blood Culture Test

Bloodstream Infection Tests | VERIGENE™ Gram-Positive Blood Culture Test

 
The VERIGENE™ Gram-Positive Blood Culture Test (BC-GP) identifies genus, species, and genetic resistance determinants for a broad panel of gram-positive bacteria directly from positive blood culture bottles

While conventional microbiological methods may require 2-4 days to produce bacterial identification and susceptibility results, VERIGENE Gram-Positive Blood Culture (BC-GP) Test provides results within 2.5 hours of blood culture positivity.

 

Gram-positive bacteria are also a common source of contamination during blood draws, which results in clinically-irrelevant positive blood cultures. This can lead to inappropriate antimicrobial use1 and wasted time and cost. Patients with contaminated blood culture bottles are often presumptively treated for bloodstream infections for several days until the organism can be identified as a contaminant using conventional biochemical methods.

 

Neelam Dhiman, PhD, Scientific Director, Molecular ID, at med fusion speaks about the impact of the VERIGENE® BC-GP Test, which has been able to reduce time to patient therapy and increase cost savings. Watch this short, three minute video to learn more.

Gram-Positive Blood Culture Test Specifications

 

Targets U.S./FDA-Cleared Outside U.S.
Species
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus lugdunensis
Streptococcus anginosus Group
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Enterococcus faecalis
Enterococcus faecium
Genus
Staphylococcus spp.
Streptococcus spp.
Micrococcus spp.  
Listeria spp.
Resistance
mecA (methicillin)
vanA (vancomycin)
vanB (vancomycin)

 

Key Features
Automation Sample to Result
Instrumentation VERIGENE Reader and Processor SP
Workflow On-Demand and Scalable
Sample Type Positive Blood Culture Bottle
Hands-On Time <5 minutes
Run Time <2.5 hours
†For use with all commercially available continuous monitoring blood culture bottles; see VERIGENE BC-GP package insert for details.

 

 

Resources

 

VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) (IVD)Product Information


California Hospital System Uses VERIGENE System to Address Antibiotic ResistanceBlog


Leading Pediatrics Hospital Finds Rapid Testing Reduces Unnecessary Use of AntibioticsBlog


Luminex Case Study: Med Fusion & VERIGENEVideo


Each Hour Counts: The Clinical and Economic Case for Rapid Sepsis DiagnosticsWebinar


Each Hour Counts: Optimizing Therapy for Bloodstream Infections with Rapid Molecular TestingWebinar


Each Hour Counts: Improving Management of CRE’s and Other Antibiotic-Resistant BSI’s with Rapid Molecular DiagnosticsWebinar


Each Hour Counts: Physician and Pharmacist Perspectives on the Value of Rapid Blood Culture TestingWebinar


Justification, Validation and Implementation Best Practices for Multiplex Molecular Infectious Disease TestsWebinar


Impact of a Rapid Blood Culture Assay for Gram-Positive Identification and Detection of Resistance Markers in a Pediatric HospitalArticle


Impact of a Rapid Blood Culture Assay for Gram-Positive Identification and Detection of Resistance Markers in a Pediatric HospitalArch Pathol Lab Med

Ordering Information

 

Luminex Online Order Management
Email: [email protected]
Phone: 1-512-336-3550
Toll Free: 1-866-401-5450
Fax: 1-512-219-0544
Fax (Europe, Middle East, India, Asia): +31 (0)73 800 1998
Product Name Kit Size Registration
Status
Part Number
VERIGENE® Gram-Positive Blood Culture Test (BC-GP) Kit 20 BC-GP Test Cartridges
20 Extraction Trays
US-IVD
CE Marked
20-005-018
VERIGENE® Gram-Positive Blood Culture Test (BC-GP) Utility Reagent Kit

20 BC-GP Utility Trays US-IVD
CE Marked
20-012-018

 

  1. von Eiff C, Herrmann M, Peters G. 1995. Antimicrobial susceptibilities of Stomatococcus mucilaginosus and of Micrococcus spp. Antimicrob Ag Chemo. 39:268-270.

 

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.

Intended Use

The VERIGENE Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) performed using the sample-to-result Verigene System is a qualitative, multiplexed in vitro diagnostic test for the simultaneous detection and identification of potentially pathogenic gram-positive bacteria which may cause bloodstream infection (BSI). BC-GP is performed directly on blood culture bottles identified as positive by a continuous monitoring blood culture system and which contain gram-positive bacteria.

BC-GP detects and identifies the following bacterial genera and species: Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus spp., Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, Enterococcus faecalis, Enterococcus faecium, Listeria spp., and Micrococcus spp.

In addition, BC-GP detects the mecA resistance marker, inferring mecA-mediated methicillin resistance, and the vanA and vanB resistance markers, inferring vanA/vanB-mediated vancomycin resistance. In mixed growth, BC-GP does not specifically attribute van-mediated vancomycin resistance to either E. faecalis or E. faecium, or mecA-mediated methicillin resistance to either S. aureus or S. epidermidis.

BC-GP is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial bloodstream infections; however, is not to be used to monitor these infections. Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, identification of organisms not detected by BC-GP, differentiation of mixed growth, association of antimicrobial resistance marker genes to a specific organism, or for epidemiological typing.